Skip to menu Skip to content Skip to footer
Associate Professor Peter Mollee
Associate Professor

Peter Mollee

Email: 

Overview

Background

Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.

Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.

Availability

Associate Professor Peter Mollee is:
Available for supervision

Qualifications

  • Masters (Coursework) of Medical Science, University of Newcastle
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians
  • Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia

Research impacts

The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.

Works

Search Professor Peter Mollee’s works on UQ eSpace

332 works between 1997 and 2025

181 - 200 of 332 works

2015

Journal Article

Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients

Taylor, Emma, Jones, Mark, Hourigan, Matthew J., Johnson, David W., Gill, Devinder S., Isbel, Nicole, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher K., Campbell, Scott B. and Mollee, Peter (2015). Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. Nephrology Dialysis Transplantation, 30 (10), 1774-1779. doi: 10.1093/ndt/gfv260

Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients

2015

Conference Publication

Comparison of Freelite (TM) and N Latex serum free light chain assays in subjects with end stage renal disease on haemodialysis

Kennard, A., Hawley, C., Tate, J., Klingberg, S., Pretorius, C. and Mollee, P. (2015). Comparison of Freelite (TM) and N Latex serum free light chain assays in subjects with end stage renal disease on haemodialysis. 51st Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Canberra, ACT, Australia, 7-9 September 2015. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/nep.12543

Comparison of Freelite (TM) and N Latex serum free light chain assays in subjects with end stage renal disease on haemodialysis

2015

Conference Publication

LECT2 Amyloidosis: not just a Hispanic disease

Ramzy, J., Mollee, P., Kwok, F., Gilbertson, J., Hosking, P., Fraenkel, M., Renaut, P., Stewart, G., Booth, D. and Gibbs, S. (2015). LECT2 Amyloidosis: not just a Hispanic disease. 15th International Myeloma Workshop, Rome, Italy, 23-26 September 2015. New York, NY United States: Elsevier. doi: 10.1016/j.clml.2015.07.414

LECT2 Amyloidosis: not just a Hispanic disease

2015

Conference Publication

Developing safe haematological monitoring guidelines for patients with myeloma on bortezomib based regimens

Woodrow, C. and Mollee, P. (2015). Developing safe haematological monitoring guidelines for patients with myeloma on bortezomib based regimens. 15th International Myeloma Workshop, Rome, Italy, 23-26 September 2015. New York, NY United States: Elsevier. doi: 10.1016/j.clml.2015.08.097

Developing safe haematological monitoring guidelines for patients with myeloma on bortezomib based regimens

2015

Journal Article

International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with cd20-positive b cell ptld: Clues from the ptld-1 trial

Trappe, R. U., Choquet, S., Dierickx, D., Mollee, P., Zaucha, J. M., Dreyling, M. H., Duehrsen, U., Tarella, C., Shpilberg, O., Sender, M., Salles, G., Morschhauser, F., Jaccard, A., Lamy, T., Reinke, P., Neuhaus, R., Lehmkuhl, H., Horst, H. A., Leithaeuser, M., Schlattmann, P., Anagnostopoulos, I., Raphael, M., Riess, H., Leblond, V. and Oertel, S. (2015). International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with cd20-positive b cell ptld: Clues from the ptld-1 trial. American Journal of Transplantation, 15 (4), 1091-1100. doi: 10.1111/ajt.13086

International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with cd20-positive b cell ptld: Clues from the ptld-1 trial

2015

Journal Article

Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Weber, N., Mollee, P., Augustson, B., Brown, R., Catley, L., Gibson, J., Harrison, S., Ho, P. J., Horvath, N., Jaksic, W., Joshua, D., Quach, H., Roberts, A. W., Spencer, A., Szer, J., Talaulikar, D., To, B., Zannettino, A. and Prince, H. M. (2015). Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45 (4), 371-382. doi: 10.1111/imj.12566

Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

2015

Journal Article

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A., Harrison, S., Mollee, P., Roberts, A. W., Horvath, N., Talaulikar, D., To, B., Zannettino, A., Brown, R., Catley, L., Augustson, B., Jaksic, W., Gibson, J. and Prince, H. M. (2015). Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45 (3), 335-343. doi: 10.1111/imj.12688

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

2015

Journal Article

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A., Harrison, S. J., Mollee, P., Roberts, A. W., Horvath, N., Talulikar, D., To, B., Zannettino, A., Brown, R., Catley, L., Augustson, B., Jaksic, W., Gibsonm J. and Prince, H. M. (2015). Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 45 (1), 94-105. doi: 10.1111/imj.12640

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

2015

Journal Article

Intravenous oxycontin-associated thrombotic microangiopathy treated successfully without plasma exchange

Tate, Courtney and Mollee, Peter (2015). Intravenous oxycontin-associated thrombotic microangiopathy treated successfully without plasma exchange. Medical Journal of Australia, 202 (6), 330-332. doi: 10.5694/mja14.01125

Intravenous oxycontin-associated thrombotic microangiopathy treated successfully without plasma exchange

2015

Conference Publication

Emergence of Fc gamma RIIb-dominance contributes to resistance to therapeutic antibodies in chronic lymphocytic leukemia patients

Burgess, Melinda, Gill, Devinder, Mapp, Sally, Ellis, Jonathan, Cheung, Catherine, Chambers, Lynne, Mattarollo, Stephen, Mollee, Peter and Saunders, Nicholas (2015). Emergence of Fc gamma RIIb-dominance contributes to resistance to therapeutic antibodies in chronic lymphocytic leukemia patients. XVI International Workshop on Chronic Lymphocytic Leukaemia 2015, Sydney, NSW, Australia, 6–9 September 2015. Abingdon, Oxfordshire, United Kingdom: Taylor & Francis.

Emergence of Fc gamma RIIb-dominance contributes to resistance to therapeutic antibodies in chronic lymphocytic leukemia patients

2015

Conference Publication

Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis

Mollee, Peter, Renaut, Patricia, Boros, Samuel, Loo, Dorothy and Hill, Michelle (2015). Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis. 57th Annual Meeting of the American-Society-of-Hematology, Orlando, FL United States, 5-8 December 2015. Washington, DC United States: American Society of Hematology.

Diagnosis of Amyloidosis Subtype By Laser-Capture Microdissection (LCM) and Tandem Mass Spectrometry (MS/MS) Proteomic Analysis

2015

Conference Publication

Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study

Mollee, P., Law, W. Phillip, Wang, W. Y. S, Moore, P. T. and Ng, A. C. T (2015). Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study. International Myeloma Workshop, Rome, Italy, 23-26 September 2015. New York, NY United States: Elsevier. doi: 10.1016/j.clml.2015.07.416

Cardiac amyloid imaging with 18F-florbetaben positron emission tomography: a pilot study

2014

Journal Article

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

Benboubker, Lotfi, Dimopoulos, Meletios A, Dispenzieri, Angela, Catalano, John, Belch, Andrew R, Cavo, Michele, Pinto, Antonello, Weisel, Katja, Ludwig, Heinz, Bahlis, Nizar, Banos, Anne, Tiab, Mourad, Delforge, Michel, Cavenagh, Jamie, Geraldes, Catarina, Lee, Je-Jung, Chen, Christine, Oriol, Albert, de la Rubia, Javier, Qiu, Lugui, White, Darrell J, Binder, Daniel, Anderson, Kenneth, Fermand, Jean-Paul, Moreau, Philippe, Attal, Michel, Knight, Robert, Chen, Guang, Van Oostendorp, Jason ... Mollee, Peter (2014). Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. The New England Journal of Medicine, 371 (10), 906-17. doi: 10.1056/NEJMoa1402551

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

2014

Journal Article

Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients

Jackson, Kathryn, Kennedy, Glen, Mollee, Peter, Marlton, Paula and Morris, Kirk (2014). Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients. Asia-Pacific Journal of Clinical Oncology, 10 (3), 246-254. doi: 10.1111/ajco.12188

Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients

2014

Journal Article

Successful treatment of iatrogenic multicentric castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient

Speicher, D. J., Sehu, M. M., Mollee, P., Shen, L., Johnson, N. W. and Faoagali, J. L. (2014). Successful treatment of iatrogenic multicentric castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient. American Journal of Transplantation, 14 (5), 1207-1213. doi: 10.1111/ajt.12693

Successful treatment of iatrogenic multicentric castleman's disease arising due to recrudescence of HHV-8 in a liver transplant patient

2014

Journal Article

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Tan, P., Wei, A., Mithraprabhu, S., Cummings, N., Liu, H. B., Perugini, M., Reed, K., Avery, S., Patil, S., Walker, P., Mollee, P., Grigg, A., D'Andrea, R., Dear, A. and Spencer, A. (2014). Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer Journal, 4 (1) e170, e170-e170. doi: 10.1038/bcj.2013.68

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

2014

Journal Article

How to diagnose amyloidosis

Mollee, P., Renaut, P., Gottlieb, D. and Goodman, H. (2014). How to diagnose amyloidosis. Internal Medicine Journal, 44 (1), 7-17. doi: 10.1111/imj.12288

How to diagnose amyloidosis

2014

Conference Publication

New diagnostic strategies for assessment of amyloidosis and myeloma

Mollee, Peter (2014). New diagnostic strategies for assessment of amyloidosis and myeloma. 48th Annual Scientific Meeting of the Australasian Division of the IAP, Brisbane, QLD Australia, 31 May – 2 June 2024. Oxford, United Kingdom: Elsevier. doi: 10.1097/01.pat.0000443473.89668.b2

New diagnostic strategies for assessment of amyloidosis and myeloma

2014

Journal Article

Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry

Adams, Rebecca L. C., Cheung, Catherine, Banh, Raymond, Saal, Russell, Cross, Donna, Gill, Devinder, Self, Marlene, Klein, Kerenaftali and Mollee, Peter (2014). Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. Cytometry Part B - Clinical Cytometry, 86 (2), 80-90. doi: 10.1002/cyto.b.21138

Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry

2014

Conference Publication

Recommendations for Serum Free Light Chains (Sflc) Measurement in Routine Laboratories

Tate, Jill, Jovanovich, Sue, Mollee, Peter, Chiu, Weldon, Wienholt, Louise, Gillis, David, Reibelt, Lindsay and Youdell, Odette (2014). Recommendations for Serum Free Light Chains (Sflc) Measurement in Routine Laboratories. Unknown, Unknown, Unknown. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia.

Recommendations for Serum Free Light Chains (Sflc) Measurement in Routine Laboratories

Funding

Past funding

  • 2022 - 2023
    Laser capture microdissection to empower cancer discoveries, improve diagnosis, treatment and outcomes in amyloidosis patients
    IPF Healthy - Medical Research
    Open grant
  • 2019 - 2023
    Frailty-stratified randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma - the FRAIL-M study (MRFF LSCD Grant Administered by Monash)
    Monash University
    Open grant
  • 2018 - 2025
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant
  • 2017 - 2021
    Benefit of 2D-strain surveillance in improving cardiovascular outcomes in cancer patients undergoing cardiotoxic chemotherapy
    Baker IDI Heart & Diabetes Institute
    Open grant
  • 2013 - 2020
    The Diamantina Individualised Oncology Care Centre (DIOCC)
    Australian Cancer Research Foundation
    Open grant
  • 2007
    Valproic acid and cytarabine therapy for elderly or relapsed acute myeloid leukaemia
    Leukaemia Foundation
    Open grant

Supervision

Availability

Associate Professor Peter Mollee is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Supervision history

Current supervision

Media

Enquiries

For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au